Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.19
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nuformix Rises As NXP001 Passes "Major" Pre-Clinical Milestone

Fri, 14th Sep 2018 10:17

LONDON (Alliance News) - Shares in pharmaceutical firm Nuformix PLC rose Friday it has received a GBP500,000 payment after its NXP001 product reached a pre-clinical milestone.

Nuformix was trading at 2.70 pence a share on Friday morning, up 10%.

The company said, as part of its agreement with Newsummit Biopharma, it will get a further GBP2 million from Newsummit when NXP001 shows human bioequivalence.

Newsummit has exclusive rights to market and distribute NXP001 in China, and Nuformix said it is in talks with other parties over marketing for the product in other regions.

Nuformix uses co-crystal technology to unlock the therapeutic potential of approved drugs, and it has programmes in both oncology supportive care and fibrosis.

Chief Executive Dan Gooding said: "We are delighted to reach this first major milestone for NXP001 and Nuformix. The results from studies conducted by NSB have triggered the first payment, which we will receive shortly.

"NSB remain committed to securing market approval for NXP001 in China and we continue to provide support to that process. Our human pharmacokinetic study remains on track at UK-based CRO, Quotient Sciences and success within that study will trigger the second GBP2 million payment and allow us to conclude further licensing agreements for Rest of World marketing rights."

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

Wednesday 13 March 
abrdn China Investment Co LtdGM re liquidation
Safestore Holdings PLCAGM
Wincanton PLCGM re takeover by CEVA Logistics
Thursday 14 March 
Angus Energy PLCGM
Bank of Georgia Group PLCGM re acquisition of Ameriabank CJSC
Blackrock Sustainable American Income Trust PLCAGM
Friday 15 March 
BlackRock Energy & Resources Income Trust PLCAGM
Chrysalis Investments LtdAGM
Quantum Exponential Group PLCGM re delisting from AQSE
TruSpine Technologies PLCAGM (adjourned 2022)
United Oil & Gas PLCGM re fundraise and share sub-division
Monday 18 March 
MGC Pharmaceuticals LtdGM re change of company name to Argent Biopharma
Schroder European Real Estate Investment Trust PLCAGM
Tuesday 19 March 
BlackRock Throgmorton Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Eco Animal Health Group PLCGM re share buybacks
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Nuformix PLCAGM
Scirocco Energy PLCGM re requisitioned resolution to implement cash strategy
Various Eateries PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis.

Read more
18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year.

Read more
17 Aug 2023 15:43

UK shareholder meetings calendar - next 7 days

Friday 18 August 
Adams PLCAGM
ME Group International PLCGM re proposed share buyback
Oxford BioDynamics PLCGM re placing
Pathfinder Minerals PLCGM re disposal of the subsidiary
Monday 21 August 
Calculus VCT PLCAGM
Home REIT PLCGM re changes to the investment policy
Tuesday 22 August 
Cake Box Holdings PLCAGM
ReNeuron Group PLCAGM
RUA Life Sciences PLCAGM
Smoove PLCAGM
STM Group PLCAGM
Wednesday 23 August 
Brandshield Systems PLCAGM
James Latham PLCAGM
LifeSafe Holdings PLCGM re shareholder circular
Momentum Multi-Asset Value Trust PLCGM re appointment of the liquidators
Sovereign Metals LtdGM re share placement options
Thor Energy PLCGM re proposed share consolidation
Thursday 24 August 
Ananda Developments PLCAGM
Concurrent Technologies PLCAGM
CyanConnode Holdings PLCAGM
Nuformix PLCAGM
Oryx International Growth Fund LtdAGM
ThomasLloyd Energy Impact Trust PLCAGM
ThomasLloyd Energy Impact Trust PLCGM re market purchases of its own ordinary shares
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 May 2023 12:45

Nuformix loss narrows; near-term goal to focus on NXP002 asset

(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Apr 2023 12:14

Nuformix raises GBP70,000 to fund NXP002 programme

(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Feb 2023 12:12

Nuformix progresses NXP002 trial after acquiring human tissue

(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Read more
13 Dec 2022 14:54

Nuformix interim loss virtually flat as continues work on drugs

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.

Read more
23 Sep 2022 21:02

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Aug 2022 16:01

UK shareholder meetings calendar - next 7 days

Friday 19 August 
Braemar Shipping Services PLCAGM
Citius Resources PLCAGM
Next Fifteen Communications Group PLCGM re acquisition of M&C Saatchi
Volex PLCAGM
Monday 22 August 
African Pioneer PLCAGM
Argentex Group PLCAGM
Nostrum Oil & Gas PLCGM operational update
Ondo InsurTech PLCAGM
Sabien Technology Group PLCGM re broker option
Scottish Investment Trust PLCGM re recombination of assets with JPMorgan Global Growth & Income plc
Trackwise Designs PLCAGM
Tuesday 23 August 
Bezant Resources PLCAGM
Livermore Investments Group LtdAGM
Xtract Resources PLCAGM
Wednesday 24 August 
Amur Minerals CorpGM subsidiary sale
Creightons PLCAGM
Goldstone Resources LtdAGM
Thursday 25 August 
Ince Group PLCGM fundraising
McBride PLCGM increase in borrowing limit
NatWest Group PLCGM re approval of special dividend
Nuformix PLCAGM
Triple Point Energy Efficiency Infrastructure Co PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Aug 2022 11:14

IN BRIEF: Nuformix shares rise on tolerability studies completion

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.